Maryland Attorney General Anthony G. Brown announced that Maryland joined a coalition of 48 states and territories in reaching settlements totaling $17.85 million with Lannett Company, Inc. and Bausch Health US, LLC and its affiliate Bausch Health Americas.
The settlements resolve allegations that the companies participated in long-running schemes to inflate prices, limit competition, and restrain trade involving generic prescription drugs. Under the agreements, both companies will cooperate with ongoing multistate litigation and implement internal compliance reforms. The settlements follow earlier agreements with other manufacturers totaling $49.1 million, as states prepare for the first trial in the broader case, expected in late 2026.
Officials also announced that 42 states and territories, including Maryland, filed a new lawsuit against Novartis and its generic drug affiliates Sandoz AG and Sandoz Group AG, alleging coordinated efforts to fix prices, divide markets, and manipulate bids for dozens of generic drugs. The complaint further alleges that corporate restructuring was used to limit potential liability. The multistate cases are based on years of investigations involving document reviews, phone records, and cooperating witnesses. State officials said consumers who purchased certain generic drugs between 2009 and 2019 may be eligible for compensation, while litigation against multiple companies and executives remains ongoing.
